PMID- 32702222
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1738-1088 (Print)
IS  - 2093-4327 (Electronic)
IS  - 1738-1088 (Linking)
VI  - 18
IP  - 3
DP  - 2020 Aug 31
TI  - One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world 
      Naturalistic Study.
PG  - 434-444
LID - 10.9758/cpn.2020.18.3.434 [doi]
AB  - OBJECTIVE: The aim the study was to calculate remission, recovery and relapse 
      rates in first episode patients with schizophrenia (FES) vs. patients at a later 
      phase (non-FES). METHODS: Thirty-two FES and 101 non-FES patients took part in 
      the study. The assessment included testing at baseline and at 1 year with the 
      Positive and Negative Syndrome Scale (PANSS), Calgary Depression scale, 
      State-Trait Anxiety Inventory (STAI), Udvalg for Kliniske Undersogelser (UKU) 
      scale, Simpson Angus, and General Assessment of Functioning (GAF) subscale. The 
      statistical analysis included chi-square test and analysis of covariance. 
      RESULTS: At baseline 15.62% FES vs. 10.89% non-FES patients were in remission; 
      none of FES vs. 2.97% non-FES patients were in recovery. At endpoint, the 
      respective figures were 12.50% vs. 25.00% and 3.12% vs. 3.96%. None of the 
      differences in rates was significant between the two groups except from the 
      percentage of patients being under medication (higher in the non-FES group). 
      Baseline PANSS negative subscale (PANSS-N) was the only predictor of the outcome 
      at endpoint. CONCLUSION: The current study reported very low rates of remission 
      and recovery of patients with schizophrenia without any differences between FES 
      and non-FES patients. One possibility is that the increased antipsychotic 
      treatment compensates for the worsening of the illness with time. An accumulating 
      beneficial effect of antipsychotic treatment suggested that early lack of 
      remission is not prognostic of a poor outcome.
FAU - Fountoulakis, Konstantinos N
AU  - Fountoulakis KN
AUID- ORCID: 0000-0001-5503-0811
AD  - 3rd Department of Psychiatry, School of Medicine, Aristotle University of 
      Thessaloniki, Thessaloniki, Greece.
FAU - Panagiotidis, Panagiotis
AU  - Panagiotidis P
AD  - 3rd Department of Psychiatry, School of Medicine, Aristotle University of 
      Thessaloniki, Thessaloniki, Greece.
FAU - Theofilidis, Antonis T
AU  - Theofilidis AT
AD  - 3rd Department of Psychiatry, School of Medicine, Aristotle University of 
      Thessaloniki, Thessaloniki, Greece.
FAU - Nimatoudis, Ioannis
AU  - Nimatoudis I
AD  - 3rd Department of Psychiatry, School of Medicine, Aristotle University of 
      Thessaloniki, Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Clin Psychopharmacol Neurosci
JT  - Clinical psychopharmacology and neuroscience : the official scientific journal of 
      the Korean College of Neuropsychopharmacology
JID - 101207332
PMC - PMC7383004
OTO - NOTNLM
OT  - Antipsychotics
OT  - Early intervention
OT  - First episode schizophrenia
OT  - Long-term
OT  - Maintenance
OT  - Outcome
OT  - Schizophrenia
COIS- Conflicts of Interest No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
PMCR- 2020/08/31
CRDT- 2020/07/24 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/04/04 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
PHST- 2020/08/31 00:00 [pmc-release]
AID - cpn.2020.18.3.434 [pii]
AID - CPN-18-434 [pii]
AID - 10.9758/cpn.2020.18.3.434 [doi]
PST - ppublish
SO  - Clin Psychopharmacol Neurosci. 2020 Aug 31;18(3):434-444. doi: 
      10.9758/cpn.2020.18.3.434.